Aquestive Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Aquestive Therapeutics, Inc. (AQST) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.57 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2020-11-04
- Aquestive Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-09-30 was $1.66M.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-06-30 was -$662.00K, a 144.82% decline year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-03-31 was -$3.58M.
- Aquestive Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-09-30 was -$3.80M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month |
|---|---|---|---|
| 2020-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $1.00M derived: sum of 2 quarters · filed 2020-11-04 | -$2.57M 10-Q · filed 2020-11-04 |
| 2020-06-30 | -$662.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$4.24M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | -$3.58M 10-Q · filed 2020-05-05 | ||
| 2019-09-30 | -$3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$2.33M derived: sum of 2 quarters · filed 2020-11-04 | -$5.63M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$1.83M 10-Q · filed 2020-08-04 | |
| 2019-03-31 | -$3.31M 10-Q · filed 2020-05-05 | ||
| 2018-09-30 | -$839.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $3.48M derived: sum of 2 quarters · filed 2019-11-05 | $2.75M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $4.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $3.59M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | -$721.00K 10-Q · filed 2019-05-08 | ||
| 2017-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $4.22M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$380.00K 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |